Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05796765 · ClinicalTrials.gov registry record · Phase 2
Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis
A Phase 2 study, sponsored by MiMedx Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT05796765: Clinical Trial Phase 2 study, sponsored by MiMedx Group.
NCT05796765 is a Phase 2 study that was terminated before completion, run by MiMedx Group. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05796765, a Phase 2 study, was terminated before completion, sponsored by MiMedx Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of the 40 mg and 100 mg doses of allogeneic micronized dehydrated human amnion/chorion membrane (micronized DHACM) injectable compared to 0.9% sodium chloride injection, placebo control for the treatment of knee osteoarthritis
Primary Outcome
Efficacy Endpoint
Interventions
- DRUG Saline
- BIOLOGICAL Micronized DHACM 40 mg
- BIOLOGICAL Micronized DHACM 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 2 |
Why NCT05796765 stopped before completion
NCT05796765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT05796765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05796765 about?
NCT05796765 is a clinical study titled "Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis". The purpose of this study is to determine the safety and efficacy of the 40 mg and 100 mg doses of allogeneic micronized dehydrated human amnion/chorion membrane (micronized DHACM) injectable compared to 0.9% sodium chloride injection, placebo control for the treatment of knee osteoarthritis
What is the current status of trial NCT05796765?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2023-03-24. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05796765?
The interventions under investigation include: Saline (DRUG), Micronized DHACM 40 mg (BIOLOGICAL), Micronized DHACM 100 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT05796765?
This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05796765's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI